Participants of the “Longevity - pharmtech in the service of eternal life” session at Open Innovations have discussed trends in medicine and pharmaceuticals related to technologies that can slow down aging and stop age-related diseases.

Leonid Melamed, Chairman of the Board of Directors of Team Drive, noted the rapid development of the anti-aging market in pharmaceuticals. According to him, hundreds of promising drug concepts aimed at slowing aging have already been developed, and the number of clinical trials has doubled during 10 years.

“In 2012, 73 tests were carried out, in 2018 already 145. In the coming years, we are likely to expect another boom. But, as you know, clinical trials in humans are a very expensive initiative. They are conducted only after a promising drug concept has been formed and laboratory tests have been completed”, - Leonid Melamed emphasized.

Representatives of foreign pharmaceutical companies told which projects are actively developing in their countries. Cecil Kai, senior analyst at Chinese 36Kr information platform, noted the growth of the stem cell market worldwide and, in particular, in China.

“It is expected that in the next five years the volume of this market will grow to 10 trillion dollars. There is a shortage of stem cell technology in the Chinese market. Therefore, we are going to conclude agreements with various international companies in order to bring new technologies to our market”, said Cecil Kai.

Summing up the discussion, Vadim Kukava, Executive Director of the Pharma Innovation Association, added that the speed of development of the pharmtech sector in any country depends on the effectiveness of the state regulatory policy.